MITCHELL CAGLE: Open Payments
NPI 1306396676 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,860 in 107 payments from 21 companies in 2025. Trend: 2023 $2,981 · 2024 $2,106 · 2025 $1,860
Food & beverage: $1,860
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 11 | $217 |
| AstraZeneca Pharmaceuticals LP | 11 | $203 |
| Amgen Inc. | 17 | $195 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $171 |
| Esperion Therapeutics, Inc. | 10 | $167 |
| Lilly USA, LLC | 9 | $161 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $137 |
| Novo Nordisk Inc | 5 | $85 |
| Novartis Pharmaceuticals Corporation | 5 | $81 |
| ABBVIE INC. | 4 | $76 |
Products named: JARDIANCE, ELIQUIS, NEXLETOL, MOUNJARO, Kerendia, FARXIGA, OTEZLA, AIRSUPRA.
Industry payments across AL — which companies pay providers there.
